Publication:
Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.

dc.contributor.authorZafrir, Barak
dc.contributor.authorLund, Lars H
dc.contributor.authorLaroche, Cecile
dc.contributor.authorRuschitzka, Frank
dc.contributor.authorCrespo-Leiro, Maria G
dc.contributor.authorCoats, Andrew J S
dc.contributor.authorAnker, Stefan D
dc.contributor.authorFilippatos, Gerasimos
dc.contributor.authorSeferovic, Petar M
dc.contributor.authorMaggioni, Aldo P
dc.contributor.authorDe-Mora-Martin, Manuel
dc.contributor.authorPolonski, Lech
dc.contributor.authorSilva-Cardoso, Jose
dc.contributor.authorAmir, Offer
dc.contributor.groupESC-HFA HF Long-Term Registry Investigators
dc.date.accessioned2023-01-25T10:23:23Z
dc.date.available2023-01-25T10:23:23Z
dc.date.issued2018-10-15
dc.description.abstractTo investigate the characteristics long-term prognostic implications (up to ∼2.2 years) of atrial fibrillation (AF) compared to sinus rhythm (SR), between acute and chronic heart failure (HF) with reduced (HFrEF  Data from the observational, prospective, HF long-term registry of the European Society of Cardiology were analysed. A total of 14 964 HF patients (age 66 ± 13 years, 67% male; 53% HFrEF, 21% HFmrEF, 26% HFpEF) were enrolled. The prevalence of AF was 27% in HFrEF, 29% in HFmrEF, and 39% in HFpEF. Atrial fibrillation was associated with older age, lower functional capacity, and heightened physical signs of HF. Crude rates of mortality and HF hospitalization were higher in patients with AF compared to SR, in each EF subtype. After multivariable adjustment, the hazard ratio of AF for HF hospitalizations was: 1.036 (95% CI 0.888-1.208, P = 0.652) in HFrEF, 1.430 (95% CI 1.087-1.882, P = 0.011) in HFmrEF, and 1.487 (95% CI 1.195-1.851, P  The prevalence of AF increases with increasing EF but its association with worse cardiovascular outcomes, remained significant in patients with HFpEF and HFmrEF, but not in those with HFrEF.
dc.description.sponsorshipSince the start of EORP, the following companies have supported the program: Abbott Vascular Int. (2011–2014), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2017), Bayer AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2019), Daiichi Sankyo Europe GmbH (2011–2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2016), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2017), ResMed (2014–2016), Sanofi (2009–2011), and SERVIER (2009–2018).
dc.description.versionSi
dc.identifier.citationZafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018 Dec 21;39(48):4277-4284
dc.identifier.doi10.1093/eurheartj/ehy626
dc.identifier.essn1522-9645
dc.identifier.pmid30325423
dc.identifier.unpaywallURLhttps://academic.oup.com/eurheartj/article-pdf/39/48/4277/27206071/ehy626.pdf
dc.identifier.urihttp://hdl.handle.net/10668/13090
dc.issue.number48
dc.journal.titleEuropean heart journal
dc.journal.titleabbreviationEur Heart J
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.page.number4277-4284
dc.provenanceRealizada la curación de contenido 19/02/2025
dc.publisherOxford University Press
dc.pubmedtypeComparative Study
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.publisherversionhttps://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehy626
dc.rights.accessRightsRestricted Access
dc.subjectHeart failure
dc.subjectAtrial fibrillation
dc.subjectHospitalizations
dc.subjectMortality
dc.subjectEjection fraction
dc.subjectPrognosis
dc.subject.decsPrevalencia
dc.subject.decsFibrilación atrial
dc.subject.decsHospitalización
dc.subject.decsInsuficiencia cardíaca
dc.subject.decsCardiología
dc.subject.decsAdaptación psicológica
dc.subject.meshAged
dc.subject.meshAtrial Fibrillation
dc.subject.meshCardiology
dc.subject.meshCause of Death
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHeart Failure
dc.subject.meshHospitalization
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPrevalence
dc.subject.meshPrognosis
dc.subject.meshProspective Studies
dc.subject.meshSocieties, Medical
dc.subject.meshStroke Volume
dc.titlePrognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number39
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format